Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Raily Aesthetic Medicine International Holdings Limited ( (HK:2135) ) just unveiled an announcement.
Raily Aesthetic Medicine International Holdings Limited has announced that its subsidiary Miusee Beauty and a target company have entered into a subscription agreement with two external investors, under which 233,335 new shares of the target company will be issued for a total subscription price of HK$3.5 million. Upon completion, Miusee Beauty, the first investor and the second investor will hold 30%, 51% and 19% of the target company respectively, making the target company an indirect non-wholly owned subsidiary whose financial results will be consolidated into Raily’s group accounts; the deal qualifies as a discloseable transaction under Hong Kong listing rules, requiring reporting and announcement but not shareholder approval, and signals a further build-out of Raily’s footprint in the aesthetic medicine segment through minority external capital participation.
The most recent analyst rating on (HK:2135) stock is a Hold with a HK$0.14 price target. To see the full list of analyst forecasts on Raily Aesthetic Medicine International Holdings Limited stock, see the HK:2135 Stock Forecast page.
More about Raily Aesthetic Medicine International Holdings Limited
Raily Aesthetic Medicine International Holdings Limited is an investment holding company in the aesthetic medicine sector, operating through subsidiaries such as Miusee Beauty. The group focuses on aesthetic and beauty-related medical services and investments, targeting the growing demand for cosmetic and aesthetic treatments in its core markets.
Average Trading Volume: 978,505
Technical Sentiment Signal: Buy
Current Market Cap: HK$79.1M
For an in-depth examination of 2135 stock, go to TipRanks’ Overview page.